A drug aimed at helping women who've lost their sex drive cleared a key hurdle Thursday, winning backing from an FDA panel.

An FDA advisory committee voted 18-6 to recommend that the FDA approve the drug flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.

The panel's recommendation will be given to the Food and Drug Administration, which will ultimately decide whether to approve the drug, dubbed by some as "female Viagra." The FDA often follows the recommendations made by advisory committees but is not required to do so.

There's no doubt that sex drugs for men have been a boon for the pharmaceutical industry. The FDA approved Viagra in 1998. And last year, the drug earned more than $1.6 billion for Pfizer.

But drug companies have struggled to come up with the right formula for women.

According to a 2002 study, up to one-third of adult women might experience hypoactive sexual desire disorder -- the technical term for when women have a lack or absence of sexual desire or fantasy. But some experts say that for women, the cure for low libido is more likely to be found in their brains than in a bottle.

Experts say it's a misnomer to describe flibanserin as "Viagra for women," since the way the drug works is distinctly different. It's a drug that works on the central nervous system -- in the same category as an antidepressant.

Viagra, in contrast, focuses on the physical, treating erectile dysfunction but doing nothing to induce sexual desire.

Thursday's meeting was the third time flibanserin, made by Sprout Pharmaceuticals, was reviewed by the FDA. In the past, the FDA has rejected it, saying it had too many side effects, and really didn't turn women on anyhow.

In 2010, a committee told pharmaceutical giant Boehringer Ingelheim, which initially developed the drug, that the company should go back to the drawing board to develop more conclusive data about it. In 2013, the drug was rejected without going before the committee.

Last year, Sprout Pharmaceutical said it was preparing to conduct additional studies after the FDA had given the company "clear guidance" on "the path forward."

A 2013 study in the Journal of Sexual Medicine showed that women taking the drug reported an average increase of 2.5 satisfying sexual events in four weeks, compared with an increase of 1.5 among women using a placebo.